Zura Bio Limited (ZURA)
1.36
0.16 (13.33%)
At close: Feb 28, 2025, 3:59 PM
1.36
0.00%
After-hours: Feb 28, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 1.16 |
| Market Cap | 88.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -31.83M |
| EPS (ttm) | -0.39 |
| PE Ratio (ttm) | -3.49 |
| Forward PE | -2.2 |
| Analyst | Buy |
| Ask | 1.49 |
| Volume | 207,658 |
| Avg. Volume (20D) | 510,408 |
| Open | 1.20 |
| Previous Close | 1.20 |
| Day's Range | 1.18 - 1.36 |
| 52-Week Range | 1.17 - 6.35 |
| Beta | -0.01 |
About ZURA
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California....
Industry Biotechnology
Sector Healthcare
IPO Date Mar 21, 2023
Employees 14
Stock Exchange NASDAQ
Ticker Symbol ZURA
Website https://zurabio.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ZURA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 1002.94% from the latest price.
Buy 83.33%
Hold 16.67%
Sell 0.00%
10 months ago
+17.89%
Zura Bio shares are trading higher. The company an...
Unlock content with
Pro Subscription
